US6406867B1
(en)
|
1996-08-16 |
2002-06-18 |
Human Genome Sciences, Inc. |
Antibody to human endokine alpha and methods of use
|
US20060099171A1
(en)
*
|
2004-11-05 |
2006-05-11 |
Masahide Tone |
Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
|
JP5238936B2
(ja)
|
2005-03-25 |
2013-07-17 |
ジーアイティーアール,インク. |
Gitr結合分子およびその使用
|
US20110212086A1
(en)
*
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
KR100877978B1
(ko)
*
|
2007-01-12 |
2009-01-12 |
가천의과학대학교 산학협력단 |
Cd86 분자가 넉 다운된 형질전환 돼지 혈관 내피세포주 및 이의 제조방법
|
EP2737907A3
(en)
|
2007-05-07 |
2014-11-05 |
MedImmune, LLC |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
JP5932217B2
(ja)
|
2007-07-12 |
2016-06-08 |
ジーアイティーアール, インコーポレイテッド |
Gitr結合分子を使用する併用療法
|
US20090136446A1
(en)
*
|
2007-11-02 |
2009-05-28 |
Ludwig Institute For Cancer Research Ltd. |
Induction of regulatory t cell-resistant helper cd4+ t cells
|
US8586023B2
(en)
|
2008-09-12 |
2013-11-19 |
Mie University |
Cell capable of expressing exogenous GITR ligand
|
PL2344540T3
(pl)
|
2008-10-02 |
2018-05-30 |
Aptevo Research And Development Llc |
Białka wiążące wiele celów antagonistyczne względem cd86
|
US8709424B2
(en)
*
|
2009-09-03 |
2014-04-29 |
Merck Sharp & Dohme Corp. |
Anti-GITR antibodies
|
DK2477656T3
(en)
|
2009-09-15 |
2017-06-26 |
Csl Ltd |
TREATMENT OF NEUROLOGICAL CONDITIONS
|
GB0919054D0
(en)
*
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
WO2012003810A1
(zh)
*
|
2010-07-09 |
2012-01-12 |
中国科学院上海巴斯德研究所 |
Foxp3及调节性t细胞的调节因子及其应用
|
US8440195B2
(en)
|
2010-11-12 |
2013-05-14 |
National University Corporation Chiba University |
Inhibition of CD69 for treatment of inflammatory conditions
|
AU2012339618B2
(en)
*
|
2011-11-15 |
2017-09-07 |
The Walter And Eliza Hall Institute Of Medical Research |
Soluble mediator
|
US10260089B2
(en)
|
2012-10-29 |
2019-04-16 |
The Research Foundation Of The State University Of New York |
Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
|
CN105101995A
(zh)
|
2013-03-15 |
2015-11-25 |
宾夕法尼亚大学理事会 |
具有生物分子佐剂的疫苗
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
EA201690987A1
(ru)
|
2013-11-13 |
2016-10-31 |
Новартис Аг |
Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
|
CA2931684C
(en)
|
2013-12-19 |
2024-02-20 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
AU2015229103C9
(en)
|
2014-03-14 |
2020-11-26 |
Immutep S.A.S |
Antibody molecules to LAG-3 and uses thereof
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
EP3511328B1
(en)
|
2014-03-24 |
2021-03-03 |
Novartis AG |
Monobactam organic compounds for the treatment of bacterial infections
|
CA2940671A1
(en)
|
2014-04-07 |
2015-10-15 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
CN108064242B
(zh)
|
2014-05-28 |
2022-10-21 |
阿吉纳斯公司 |
抗gitr抗体和其使用方法
|
BR112016028378A2
(pt)
|
2014-06-06 |
2017-10-24 |
Bristol Myers Squibb Co |
anticorpos contra o receptor do fator de necrose tumoral induzido por glicocorticoide (gitr) e usos dos mesmos
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
SG11201700476VA
(en)
|
2014-07-21 |
2017-02-27 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
US10160726B2
(en)
|
2014-08-06 |
2018-12-25 |
Novartis Ag |
Quinolone derivatives as antibacterials
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
DK3183268T3
(da)
|
2014-08-19 |
2020-05-11 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
|
EP3925622A1
(en)
|
2014-09-13 |
2021-12-22 |
Novartis AG |
Combination therapies
|
CN114621969A
(zh)
|
2014-09-17 |
2022-06-14 |
诺华股份有限公司 |
用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
|
US20170209574A1
(en)
|
2014-10-03 |
2017-07-27 |
Novartis Ag |
Combination therapies
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
SG11201702895SA
(en)
|
2014-10-08 |
2017-05-30 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對pd-l1之抗體分子及其用途
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
LT3233843T
(lt)
|
2014-12-16 |
2019-12-10 |
Novartis Ag |
Izoksazolo hidroksamido rūgšties junginiai, kaip lpxc inhibitoriai
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
SG11201705293WA
(en)
|
2014-12-29 |
2017-07-28 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
JP6692826B2
(ja)
|
2015-03-10 |
2020-05-13 |
アドゥロ バイオテック,インク. |
「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
|
ES2876974T3
(es)
|
2015-04-07 |
2021-11-15 |
Novartis Ag |
Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
AU2016249005B2
(en)
|
2015-04-17 |
2022-06-16 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
WO2016196792A1
(en)
|
2015-06-03 |
2016-12-08 |
Bristol-Myers Squibb Company |
Anti-gitr antibodies for cancer diagnostics
|
WO2017009843A2
(en)
|
2015-07-16 |
2017-01-19 |
Biokine Therapeutics Ltd. |
Compositions, articles of manufacture and methods for treating cancer
|
EP3325504A1
(en)
|
2015-07-21 |
2018-05-30 |
Novartis AG |
Methods for improving the efficacy and expansion of immune cells
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
CN108780084B
(zh)
|
2015-09-03 |
2022-07-22 |
诺华股份有限公司 |
预测细胞因子释放综合征的生物标志物
|
JP2019500893A
(ja)
|
2015-11-03 |
2019-01-17 |
ヤンセン バイオテツク,インコーポレーテツド |
Pd−1及びtim−3に特異的に結合する抗体及びそれらの使用
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
WO2017096179A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Antibodies and methods of use thereof
|
WO2017096189A1
(en)
*
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
US20180371093A1
(en)
|
2015-12-17 |
2018-12-27 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
EP3389711A1
(en)
|
2015-12-18 |
2018-10-24 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
EP3393504A1
(en)
|
2015-12-22 |
2018-10-31 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
JP2019500874A
(ja)
|
2015-12-28 |
2019-01-17 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞の作製方法
|
AU2017208133B2
(en)
|
2016-01-11 |
2023-12-21 |
Universitat Zurich |
Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
|
MX2018010010A
(es)
|
2016-02-19 |
2018-11-09 |
Novartis Ag |
Compuestos tetraciclicos de piridona como antivirales.
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
CN109069638B
(zh)
|
2016-03-24 |
2022-03-29 |
璟尚生物制药公司 |
用于癌症治疗的三特异性抑制剂
|
JP7005508B2
(ja)
|
2016-03-24 |
2022-01-21 |
ノバルティス アーゲー |
ヒトライノウイルスの阻害剤としてのアルキニルヌクレオシド類似体
|
AU2017278193B9
(en)
|
2016-06-10 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-GITR antibodies and uses thereof
|
CA3026356A1
(en)
|
2016-06-14 |
2017-12-21 |
Novartis Ag |
Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
MX2018016227A
(es)
|
2016-06-24 |
2019-07-08 |
Infinity Pharmaceuticals Inc |
Terapias de combinacion.
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
CN109641947B
(zh)
|
2016-07-20 |
2023-04-14 |
犹他大学研究基金会 |
Cd229 car t细胞及其使用方法
|
WO2018031258A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
US20180044430A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
FC Engineered Anti-TNFR Superfamily Member Antibodies Having Enhanced Atonistic Activity and Methods of Using Them
|
WO2018047109A1
(en)
|
2016-09-09 |
2018-03-15 |
Novartis Ag |
Polycyclic pyridone compounds as antivirals
|
AU2017332161B2
(en)
|
2016-09-21 |
2024-07-04 |
The United States Government As Represented By The Department Of Veterans Affairs |
Chimeric antigen receptor (car) that targets chemokine receptor CCR4 and its use
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
US10525083B2
(en)
|
2016-10-07 |
2020-01-07 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
|
TW201819380A
(zh)
|
2016-10-18 |
2018-06-01 |
瑞士商諾華公司 |
作為抗病毒劑之稠合四環吡啶酮化合物
|
JOP20190100A1
(ar)
*
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
WO2018102787A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
UA124474C2
(uk)
|
2016-12-22 |
2021-09-22 |
Емджен Інк. |
БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ
|
US10537637B2
(en)
|
2017-01-05 |
2020-01-21 |
Gensun Biopharma Inc. |
Checkpoint regulator antagonists
|
EP3367098A1
(en)
*
|
2017-02-24 |
2018-08-29 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Methods for determining interaction between biological cells
|
KR20200020662A
(ko)
|
2017-04-03 |
2020-02-26 |
온콜로지, 인크. |
면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
AR111658A1
(es)
|
2017-05-05 |
2019-08-07 |
Novartis Ag |
2-quinolinonas tricíclicas como agentes antibacteriales
|
KR20200006115A
(ko)
|
2017-05-16 |
2020-01-17 |
브리스톨-마이어스 스큅 컴퍼니 |
항-gitr 효능제 항체에 의한 암의 치료
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
CN111344303A
(zh)
|
2017-06-01 |
2020-06-26 |
Xencor股份有限公司 |
结合cd123和cd3的双特异性抗体
|
US11413310B2
(en)
|
2017-06-02 |
2022-08-16 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
BR112019024291A2
(pt)
|
2017-06-09 |
2020-07-28 |
Providence Health & Services-Oregon |
utilização de cd39 e de cd103 para a identificação de células t tumorais humanas reativas para o tratamento do câncer
|
MX2019015155A
(es)
|
2017-06-29 |
2020-08-03 |
Juno Therapeutics Inc |
Modelo de raton para valorar toxicidades asociadas con inmunoterapias.
|
EP3679040B1
(en)
|
2017-09-08 |
2022-08-03 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
US20200370012A1
(en)
|
2017-10-25 |
2020-11-26 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
MA49911A
(fr)
|
2017-11-01 |
2020-06-24 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
MA50860A
(fr)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics Inc |
Récepterus chimériques d'antigène contre l'antigène de maturation des cellules b et polynucleotides codants
|
JP2021503458A
(ja)
|
2017-11-17 |
2021-02-12 |
ノバルティス アーゲー |
新規のジヒドロイソキサゾール化合物及びb型肝炎治療のためのそれらの使用
|
MA51210A
(fr)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
US12006356B2
(en)
|
2017-12-15 |
2024-06-11 |
Juno Therapeutics, Inc. |
Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
|
EP3728266A1
(en)
|
2017-12-20 |
2020-10-28 |
Novartis AG |
Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
|
WO2019166951A1
(en)
|
2018-02-28 |
2019-09-06 |
Novartis Ag |
Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
CN110305210B
(zh)
|
2018-03-27 |
2023-02-28 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
EP3788038B1
(en)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
WO2019213526A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
AU2019265822B2
(en)
|
2018-05-10 |
2024-07-18 |
Amgen Inc. |
KRAS G12C inhibitors for the treatment of cancer
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
JP2021525769A
(ja)
|
2018-06-01 |
2021-09-27 |
ノバルティス アーゲー |
Cd123及びcd3に結合する二重特異性抗体の投与
|
MA52780A
(fr)
|
2018-06-11 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
JP7369719B2
(ja)
|
2018-06-12 |
2023-10-26 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
SG11202011830SA
(en)
|
2018-06-13 |
2020-12-30 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
US20210251994A1
(en)
|
2018-06-15 |
2021-08-19 |
Flagship Pioneering Innovations V, Inc. |
Increasing immune activity through modulation of postcellular signaling factors
|
JP2021529556A
(ja)
|
2018-06-29 |
2021-11-04 |
ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. |
抗腫瘍アンタゴニスト
|
WO2020047462A2
(en)
|
2018-08-30 |
2020-03-05 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
CN113365663A
(zh)
|
2018-08-30 |
2021-09-07 |
Hcw生物科技公司 |
单链嵌合多肽和其用途
|
EP3844181A1
(en)
|
2018-08-30 |
2021-07-07 |
HCW Biologics, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
US20220364055A1
(en)
|
2018-08-31 |
2022-11-17 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
CN112823167A
(zh)
|
2018-09-07 |
2021-05-18 |
辉瑞大药厂 |
抗-αvβ8抗体和组合物及其用途
|
KR102672512B1
(ko)
|
2018-09-12 |
2024-06-10 |
노파르티스 아게 |
항바이러스 피리도피라진디온 화합물
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
US20210347851A1
(en)
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
IL305106A
(en)
|
2018-09-29 |
2023-10-01 |
Novartis Ag |
A process for producing a compound to inhibit the activity of SHP2
|
KR20210113169A
(ko)
|
2018-11-01 |
2021-09-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
|
MX2021005022A
(es)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
|
BR112021009420A2
(pt)
|
2018-11-16 |
2021-11-23 |
Juno Therapeutics Inc |
Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
MX2021005700A
(es)
|
2018-11-19 |
2021-07-07 |
Amgen Inc |
Inhibidores de kras g12c y metodos de uso de los mismos.
|
US20220088070A1
(en)
|
2018-11-30 |
2022-03-24 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
MA54543A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
MA54550A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
EP3898592A1
(en)
|
2018-12-20 |
2021-10-27 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
EP3917570A1
(en)
|
2019-01-29 |
2021-12-08 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
CN113727758A
(zh)
|
2019-03-01 |
2021-11-30 |
锐新医药公司 |
双环杂环基化合物及其用途
|
US20230148450A9
(en)
|
2019-03-01 |
2023-05-11 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
RU2734432C1
(ru)
*
|
2019-04-23 |
2020-10-16 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с GITR
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
EP3962493A2
(en)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
CA3140392A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
AU2020294797A1
(en)
|
2019-06-21 |
2021-12-23 |
HCW Biologics, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
CN114340735A
(zh)
|
2019-06-28 |
2022-04-12 |
璟尚生物制药公司 |
突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
|
CA3146693A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CA3147276A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
MX2022001181A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
JP7417715B2
(ja)
|
2019-09-26 |
2024-01-18 |
ノバルティス アーゲー |
抗ウイルスピラゾロピリジノン化合物
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
CR20220240A
(es)
|
2019-11-04 |
2022-08-03 |
Revolution Medicines Inc |
Inhibidores de ras
|
MX2022005360A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
JP2022553858A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
BR112022008858A2
(pt)
|
2019-11-08 |
2022-09-06 |
Revolution Medicines Inc |
Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
|
JP2023501528A
(ja)
|
2019-11-14 |
2023-01-18 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の改善された合成
|
TW202132271A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Kras g12c抑制劑化合物之改善的合成
|
CN114945382A
(zh)
|
2019-11-26 |
2022-08-26 |
诺华股份有限公司 |
Cd19和cd22嵌合抗原受体及其用途
|
AR120566A1
(es)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
Receptores de antígeno quiméricos y sus usos
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
EP4076434A1
(en)
|
2019-12-17 |
2022-10-26 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
KR20220124768A
(ko)
|
2020-01-07 |
2022-09-14 |
레볼루션 메디슨즈, 인크. |
Shp2 억제제 투여 및 암 치료방법
|
WO2021163618A1
(en)
|
2020-02-14 |
2021-08-19 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
US20230119606A1
(en)
*
|
2020-02-18 |
2023-04-20 |
Octagon Therapeutics, Inc. |
Immune cell modulators
|
CN115397460A
(zh)
|
2020-02-27 |
2022-11-25 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
TW202146452A
(zh)
|
2020-02-28 |
2021-12-16 |
瑞士商諾華公司 |
結合cd123和cd3之雙特異性抗體的給藥
|
US11787867B2
(en)
|
2020-03-06 |
2023-10-17 |
Regeneron Pharmaceuticals, Inc. |
Anti-GITR antibodies and uses thereof
|
CN111218530B
(zh)
*
|
2020-03-19 |
2023-10-31 |
广西壮族自治区水产科学研究院 |
荧光定量pcr检测十足目虹彩病毒1的引物组及试剂盒
|
US20230149462A1
(en)
|
2020-04-10 |
2023-05-18 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
|
JPWO2021225159A1
(pt)
*
|
2020-05-08 |
2021-11-11 |
|
|
US12024545B2
(en)
|
2020-06-01 |
2024-07-02 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
KR20230042600A
(ko)
|
2020-06-18 |
2023-03-28 |
레볼루션 메디슨즈, 인크. |
Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
|
CN116096906A
(zh)
|
2020-06-29 |
2023-05-09 |
旗舰创业创新五公司 |
工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
|
KR20230081726A
(ko)
|
2020-09-03 |
2023-06-07 |
레볼루션 메디슨즈, 인크. |
Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
|
JP2023541916A
(ja)
|
2020-09-15 |
2023-10-04 |
レボリューション メディシンズ インコーポレイテッド |
がんの治療における、ras阻害剤としてのインドール誘導体
|
JP2023549504A
(ja)
|
2020-11-13 |
2023-11-27 |
ノバルティス アーゲー |
キメラ抗原受容体(car)発現細胞との組合せ療法
|
US20240050432A1
(en)
|
2020-12-08 |
2024-02-15 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
WO2022133102A1
(en)
*
|
2020-12-18 |
2022-06-23 |
Northwestern University |
Pi3k inhibitors for protection against glucocorticoid-induced atrophy
|
CA3203111A1
(en)
|
2020-12-22 |
2022-06-30 |
Kailiang Wang |
Sos1 inhibitors and uses thereof
|
AU2022246895A1
(en)
|
2021-03-31 |
2023-10-19 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
PE20240089A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cancer
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
EP4334321A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Ras inhibitors
|
TW202307210A
(zh)
|
2021-06-01 |
2023-02-16 |
瑞士商諾華公司 |
Cd19和cd22嵌合抗原受體及其用途
|
BR112023022097A2
(pt)
|
2021-06-07 |
2023-12-19 |
Agonox Inc |
Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
|
EP4363059A1
(en)
|
2021-06-29 |
2024-05-08 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
CN118201914A
(zh)
|
2021-09-08 |
2024-06-14 |
雷多纳治疗公司 |
Papd5和/或papd7抑制剂4-氧代-1,4-二氢喹啉-3-甲酸衍生物
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023154905A1
(en)
|
2022-02-14 |
2023-08-17 |
Gilead Sciences, Inc. |
Antiviral pyrazolopyridinone compounds
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024031091A2
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
US20240174732A1
(en)
|
2022-10-05 |
2024-05-30 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
WO2024129778A2
(en)
|
2022-12-13 |
2024-06-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
CN116925206B
(zh)
*
|
2023-07-18 |
2024-04-23 |
湖南中晟全肽生物科技股份有限公司 |
Gitr相关的多肽及其应用
|